Research Article
A Pharmacokinetic Evaluation of a Pectin-Based Oral Multiparticulate Matrix Carrier of Carbamazepine
Table 3
Pharmacokinetic parameters of carbamazepine in the 4 treatment groups.
| Parameter | Treatment group (mean (standard deviation)) | value | Formulation A | Formulation B | Carbamazepine powder | Tegretol CR® |
| (h) | 12 (1.28) | 12 (1.43) | 2 (0.56) | 8 (2.23) | 0.007 | (µg/mL) | 8.45 (0.71) | 7.74 (0.70) | 1.45 (0.45) | 8.24 (0.45) | 0.001 | AUC0⟶36 (/mL) | 176.20 (7.97) | 161 (4.24) | 22.05 (1.64) | 155 (7.15) | <0.0001 | (h−1) | 0.05 (0.01) | 0.04 (0.01) | 0.08 (0.03) | 0.05 (0.02) | 0.242 | (h) | 13.75 (3.28) | 13.23 (1.90) | 8.44 (6.97) | 13.51 (2.87) | 0.691 |
|
|
Formulation A = 100 mg carbamazepine, 200 mg CPH pectin, 50 mg calcium chloride, and 50 mg HPMC; formulation B = 100 mg carbamazepine, 200 mg CPH pectin, 50 mg calcium chloride, and 50 mg HPMC.
|